Rebecca A. Brophy Partner

Experience

• Representation of Revelstoke Capital Partners, a private equity firm, in the acquisition, disposition and portfolio work for a number of its portfolio companies including, CEI Vision Partners and Critical Nurse Staffing.
• Representation of Sheridan Capital Partners, a private equity firm, in the acquisition, disposition and portfolio work for a number of its portfolio companies  including, Dermatologists of Central States and Synergy Physical Therapy Holdings.
• Representation of Assured Healthcare Partners, a private equity firm, in multiple acquisitions in the healthcare and healthcare technology space and including acquisition, disposition and portfolio work for a number of its portfolio companies, including National Partners in Healthcare.
• Representation of Hargett Hunter Capital Partners, a private equity firm, in multiple acquisitions and investments in the food and beverage space, including its investment in Marugame Udon, a Japanese noodle chain.
• Representation of a public semiconductor and global solid state LED lighting manufacturing company in multiple acquisitions, dispositions and corporate counseling matters.
• Representation of a public contract research organization in multiple acquisitions, dispositions and corporate counseling matters.
• Representation of a private materials and recycling technology company in an agreement to acquire assets from a leading supplier of high performance catalysts for $27 million in cash plus potential additional amounts via an earn out.
• Representation affiliated multidisciplinary engineering, investigation and construction companies in a sale of assets process involving multiple potential buyers, culminating in the sale of substantially all of their assets to a wireless network services company.
• Representation of a global financial services technology company in its acquisition of a leading provider of deal analytics and valuation technology.
• Representation of a SaaS company in its sale to a data integration public company.
• Representation of a leading CRO in Asia in the acquisition of CRO assets in the United States.
• Representation of a major regional distributor of industrial gases in a strategic merger of equals of two similarly situated businesses.
• Representation of a public telecommunications company in multiple acquisitions of private company strategic targets totaling approximately $750 million, including acquisitions in the United States, Colombia and Mexico.
• Representation of a public defense contractor in multiple acquisitions of private and public company strategic targets totaling approximately $500 million.
• Representation of a public information technology company in its sale valued at approximately $340 million.
• Representation of a private equity fund in its acquisition of a public health services company valued at approximately $250 million.
• Representation of venture capital funds in multiple financings of private companies, including companies in the biotechnology and fashion industries, totaling approximately $400 million.
• Representation of a privately held leading manufacturer of beverage and foodservice equipment in its sale to a public company for $108 million in cash.
• Representation of a publicly traded health services company in the acquisition of a health services division of a privately held company for $105 million in cash.
• Representation of a private biotechnology company in financings totaling approximately $50 million.
• Representation of multiple public and private companies in general corporate and governance matters including commercial agreements, board and committee advice and general corporate advice.
• Representation of a leading provider of pharmacy-based patient care solutions and medication synchronization services to independent and chain pharmacies in its approximately $41 million sale of the company to a publicly traded buyer.
• Representation of a publicly traded health information technologies and clinical research company in its acquisition of a consulting business focusing on orphan drug designations.
• Representation of a publicly traded health information technologies and clinical research company in its sale of a consulting line of business.
• Representation of a private equity fund in its acquisition of a specialty pharmaceutical company.